Envarsus
tacrolimus · Chiesi Farmaceutici S.p.A.
AUTHORISED IN THE EUWhat Envarsus is used for
Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Envarsus
- Active substance
- tacrolimus
- Disease area
- Graft Rejection
- Medicine group
- Immunosuppressants
- ATC code
- L04AD02
- Marketing authorisation holder
- Chiesi Farmaceutici S.p.A.
- Authorised in the EU since
- 2014
Official information
In India
- Tacrolimus: 326 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Envarsus used for?
Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.
What is the active substance in Envarsus?
Envarsus contains tacrolimus.
Who makes Envarsus?
The EU marketing authorisation holder is Chiesi Farmaceutici S.p.A..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU